What is InMode's Q2 revenue guidance and how does it compare to expectations?

InMode guided Q2 revenue to $95.2M–$95.4M, exceeding analyst consensus. This guidance signals sustained demand for the company's Morpheus8 RF microneedling and fractional-laser platforms despite ongoing acquisition uncertainty.

Should medspa owners buy InMode equipment now or wait for the takeover to close?

Practices considering InMode capital equipment should move quickly to clarify pricing, rebate terms, and loyalty agreements before deal closure, expected by year-end. Takeover uncertainty may delay new placements and complicate negotiations, so locking in terms now protects your investment.

Is RF microneedling and fractional laser demand still strong in 2024?

Yes—InMode's revenue beat reflects sustained adoption of RF microneedling and fractional-laser systems in both medspa and surgical settings. Demand remains resilient despite competitive pressure from Cynosure, Cutera, and Lumenis.

What is Steel Partners' takeover bid for InMode and when will it close?

Steel Partners launched a takeover bid for InMode, which is competing with a CEO-led buyout. The deal is expected to close by year-end, but uncertainty around the outcome may impact device pricing and availability during the interim period.

How does InMode's pricing power compare to competitors like Cynosure and Lumenis?

InMode maintains per-procedure pricing power and an intact installed base despite competitive pressure from Cynosure, Cutera, and Lumenis. The company's Morpheus8 platform continues to drive strong adoption and revenue growth.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty

InMode's preliminary Q2 revenue guidance exceeds consensus, signaling sustained demand for RF and fractional-laser platforms despite acquisition turmoil.

By Evan at Inside MedSpa · Jul 18, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

InMode has provided preliminary Q2 revenue guidance of $95.2M–$95.4M, ahead of analyst expectations and demonstrating continued demand for its Morpheus8 RF microneedling and fractional-laser systems. The guidance arrives amid the Steel Partners takeover bid and competing CEO-led buyout, underscoring the underlying strength of the energy-device market.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/inmode-q2-revenue-guidance-95-2-95-4-million/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty

Share

Discussion

Leave a comment

By the time it's news, it's too late.